Daliresp
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Daliresp (roflumilast; AstraZeneca/Allergan/Takeda) is an oral phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of patients with severe chronic obstructive pulmonary disease (COPD), who suffer from chronic bronchitis and frequent exacerbations. PDE4 inhibitors are thought to relax airway smooth muscle, suppress the activation of inflammatory cells, and modulate the activity of pulmonary nerves. Daliresp received US and EU approvals for use in COPD in February 2011 and July 2010, respectively. In January 2011, Mitsubishi Tanabe announced that it had terminated its agreement with Nycomed, and would not pursue further development of roflumilast for respiratory diseases. As such, Datamonitor Healthcare does not forecast Daliresp to launch in Japan.
TABLE OF CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Daliresp : Chronic obstructive pulmonary disease (COPD)
LIST OF FIGURES
9 Figure 1: Daliresp for COPD – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Daliresp for COPD
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of Daliresp for COPD
13 Figure 4: Daliresp sales for COPD across the US and major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Daliresp drug profile
7 Table 2: Daliresp Phase III data in COPD
14 Table 3: Daliresp sales for COPD across the US and major EU markets, by country ($m), 2017–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Symbicort 
Sign up to the